The Herald was informed last week of a 15-year-old special-needs Chaparral High School student who is in need of a kidney ...

J.P. Morgan’s U.S. equity analysts picked their top stocks for 2025 in healthcare, selecting “the most compelling investment ...

The acquisition combines the assets and capabilities of two companies founded by a leader in the GPR68 field, Professor ...

Morgans healthcare and life sciences experts Iain Wilkie and Scott Power give Stockhead readers their top picks for 2025.

Certa's pipeline includes further programs targeting major indications such as chronic kidney disease, focal segmental glomerulosclerosis, diabetic nephropathy, and other chronic fibrotic conditions.

ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA – Get Free Report) was the target of a large increase in short interest in November.

Rilzabrutinib is a small molecule commercialized by Sanofi, with a leading Phase III program in Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura).

ZyVersa is advancing a pipeline of first-in-class drug candidates built around two proprietary technologies. - Inflammasome ...

Travere Therapeutics' financial landscape is a mix of FDA approvals, clinical setbacks, and cash concerns, with potential for growth and revenue.

But like some others on this list, its debut was merely an entrée. A larger opportunity lies ahead, the rare kidney disease FSGS, or focal segmental glomerulosclerosis. Filspari in FSGS would be a ...

As reported by the South China Morning Post today, Everest Medicines (HKEX 1952.HK) is accelerating its journey to become a leading biopharmaceutical company in the Asia-Pacific region, driven by ...